» Articles » PMID: 38842911

RISING STARS: Evidence for Established and Emerging Forms of β-cell Death

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2024 Jun 6
PMID 38842911
Authors
Affiliations
Soon will be listed here.
Abstract

β-Cell death contributes to β-cell loss and insulin insufficiency in type 1 diabetes (T1D), and this β-cell demise has been attributed to apoptosis and necrosis. Apoptosis has been viewed as the lone form of programmed β-cell death, and evidence indicates that β-cells also undergo necrosis, regarded as an unregulated or accidental form of cell demise. More recently, studies in non-islet cell types have identified and characterized novel forms of cell death that are biochemically and morphologically distinct from apoptosis and necrosis. Several of these mechanisms of cell death have been categorized as forms of regulated necrosis and linked to inflammation and disease pathogenesis. In this review, we revisit discoveries of β-cell death in humans with diabetes and describe studies characterizing β-cell apoptosis and necrosis. We explore literature on mechanisms of regulated necrosis including necroptosis, ferroptosis and pyroptosis, review emerging literature on the significance of these mechanisms in β-cells, and discuss experimental approaches to differentiate between various mechanisms of β-cell death. Our review of the literature leads us to conclude that more detailed experimental characterization of the mechanisms of β-cell death is warranted, along with studies to better understand the impact of various forms of β-cell demise on islet inflammation and β-cell autoimmunity in pathophysiologically relevant models. Such studies will provide insight into the mechanisms of β-cell loss in T1D and may shed light on new therapeutic approaches to protect β-cells in this disease.

Citing Articles

Targeting ferroptosis: opportunities and challenges of mesenchymal stem cell therapy for type 1 diabetes mellitus.

Dai L, Wang Q Stem Cell Res Ther. 2025; 16(1):47.

PMID: 39901210 PMC: 11792594. DOI: 10.1186/s13287-025-04188-7.

References
1.
Kaestner K, Powers A, Naji A, Atkinson M . NIH Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP). Diabetes. 2019; 68(7):1394-1402. PMC: 6609987. DOI: 10.2337/db19-0058. View

2.
Preedy M, White M, Tergaonkar V . Cellular heterogeneity in TNF/TNFR1 signalling: live cell imaging of cell fate decisions in single cells. Cell Death Dis. 2024; 15(3):202. PMC: 10928192. DOI: 10.1038/s41419-024-06559-z. View

3.
Miotto G, Rossetto M, Di Paolo M, Orian L, Venerando R, Roveri A . Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2019; 28:101328. PMC: 6812032. DOI: 10.1016/j.redox.2019.101328. View

4.
Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

5.
Cookson B, Brennan M . Pro-inflammatory programmed cell death. Trends Microbiol. 2001; 9(3):113-4. DOI: 10.1016/s0966-842x(00)01936-3. View